Investment from the Alzheimer’s Drug Discovery Foundation (ADDF) aims to support the development of Coya 302, a therapeutic candidate for the treatment of frontotemporal dementia (FTD).
Coya Therapeutics Receives $5 Million Investment from the Alzheimer’s Drug Discovery Foundation
Posted on by admin
1 min read
+ There are no comments
Add yours